Reducing the on-target/off-tumor effect of PD-L1 inhibitors by improving their selectivity for the tumor microenvironment could enhance their accumulation in tumors while managing safety, thus optimizing the therapeutic window. This evidence concerns the gene CD274 and neoplasm.